Presentation TCT 2025 TCT 590: Single-Center Real world use of the Paradise Renal Denervation Catheter. Early experience from the Cleveland Clinic. Presenter: Anmol Multani October 27, 2025
Presentation TCT 2025 Symplicity Spyral™ in the Real World: Results from the Cleveland Clinic Presenter: Aravinda Nanjundappa October 27, 2025
News Daily News Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks Michael O'Riordan August 01, 2025
News Daily News No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits Michael O'Riordan July 14, 2025
News Industry News Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels June 12, 2025
News Conference News EuroPCR 2025 Meta-analysis Quashes Hopes for Routine Embolic Protection in TAVI Michael O'Riordan May 21, 2025
News Daily News CV Death Rates in Autoimmune Disorders Waning, but Still Higher in Women L.A. McKeown May 14, 2025
News Daily News Four-Dimensional Flow CMR Shows Promise in Aortic Stenosis Yael L. Maxwell May 13, 2025
News Conference News EAS 2025 Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM Yael L. Maxwell May 08, 2025
News Daily News Lorundrostat Lowers BP in Treatment-Resistant Hypertension: Advance-HTN Yael L. Maxwell April 29, 2025
News Conference News HRS 2025 GLP-1 Drugs May Have Role in Secondary Prevention of AF Todd Neale April 28, 2025
News Daily News Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI Michael O'Riordan April 22, 2025
News Daily News Mavacamten Strikes Out in Phase III Trial of Nonobstructive HCM L.A. McKeown April 15, 2025
News Conference News ACC 2025 ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a) L.A. McKeown April 10, 2025
News Conference News EHRA 2025 SWISS-APERO at 3 Years: Hints of Differences Between Amulet, Watchman Emerge Todd Neale April 09, 2025
News Conference News ACC 2025 Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection Michael O'Riordan March 30, 2025
News Conference News ACC 2025 Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT Caitlin E. Cox March 29, 2025